Clinical Studies

Backed by science. Proven over time.

  • Efficacy demonstrated in two studies, radiolabeled and clinical field trials.1 Prescribed for over 20 years to help control signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.
  • Inhibits enzymes that break down cartilage, so joint damage is reduced.1

Clinical field trials demonstrated key improvements.

  • Assessed lameness, range of motion, pain and functional disability.1
  • Dogs treated with Adequan® Canine (polysulfated glycosaminoglycan) showed a statistically significant improvement in range of motion and total orthopedic score over placebo-treated control dogs.1
Clinical Studies Canine red ball dog
Adequan Canine clinical study results

Percent improvement2

Patients treated with Adequan® Canine showed greater improvement than dogs given a placebo.

Adequan® Canine patients had better range of motion scores (p = 0.007) and total orthopedic scores (p = 0.025) at the end of treatment than at the beginning of the study.

Adequan Canine treatment improvement results
Adequan® Canine brand of polysulfated glycosaminoglycan (PSGAG)
INDICATIONS Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.
IMPORTANT SAFETY INFORMATION Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see Full Prescribing Information.
1. Adequan® Canine Package Insert, Rev 9/2021.
2. Adequan® Canine (polysulfated glycosaminoglycan) NADA 141-038 FOI Summary, 1997.

Let’s stay in touch.

Be the first to hear about important news and product information!
First, select the one that best describes you.
Then we'll take you to our sign-up page.

CANINE VETERINARY
PROFESSIONAL		 DOG OWNER
CONTACT INFORMATION
Contact Us Adverse Event Reporting Product Quality Complaints Sign Up Press Room
ABOUT ADEQUAN® CANINE
Dosing & Administration Prescribing Information Safety Information Ordering Information
AMERICAN REGENT ANIMAL HEALTH
About Us Our Brands
All trademarks are the property of American Regent, Inc
© 2022, American Regent, Inc.
PP-AC-US-0102 (v6.0) 04/2022